Table 1. Patient clinical characteristics before CAT therapy.
| Characteristic | Number (no.) of patients |
|---|---|
| Age (years) | |
| >60 | 4/11 (36.4%) |
| Sex | |
| Male | 8/11 (72.7%) |
| Advanced stage (Ann Arbor III/IV) | 9/11 (81.8%) |
| Extranodal involvement | 5/11 (45.5%) |
| Pathological type | |
| MCL | 2/11 (18.2%) |
| DLBCL | 9/11 (81.8%) |
| Cell origin of DLBCL | 8/11 (72.7%) |
| Non-germinal center B-cell type | 5/9 (55.6%) |
| Germinal center B-cell type | 4/9 (44.4%) |
| Double expressing | 2/9 (22.2%) |
| High Ki67 (positive ≥70%) | 8/11 (72.7%) |
| No. of previous courses of antineoplastic therapy | Median 12 (range, 8–34) |
| No. of previous lines of antineoplastic therapy | Median 3 (range, 2–6) |
| Large mass at first diagnosis (major axis >7 cm) | 5/11 (45.5%) |
| Large mass before infusion of anti-CD19 CAR-T cells (major axis >7 cm) | 4/11 (36.4%) |
MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; CAR, chimeric antigen receptor. Double expressing, MYC ≥40% positive, BCL2 ≥50% positive.